University Hospital Of Clermont-Ferrand
- Address
- lock Available on a paid plan
Digestive System Diseases and Liver Cancer Research
At University Hospital Of Clermont-Ferrand, clinical research in hepatogastroenterologie focuses on Digestive System Diseases and Neoplasms, with particular attention to unresectable hepatocellular carcinoma. These studies are designed to evaluate whether new treatment strategies can improve outcomes for patients with advanced liver cancer.
- Testing a new therapy combined with standard treatment for unresectable hepatocellular carcinoma
- Assessing the effectiveness of treatment approaches in liver cancer
- Comparing whether adding novel care can improve first-line results for patients with advanced disease
This research reflects a strong clinical interest in improving treatment options for difficult-to-treat digestive system cancers through more effective and patient-focused care.
Genetic Phenomena and Rare Developmental Disorders
The site is also involved in studies within Genetic Phenomena, especially rare conditions such as Megalencephaly-CApillary malformation Polymicrogyria syndrome. University Hospital Of Clermont-Ferrand contributes to research aimed at understanding how targeted therapies may support patients with complex neurodevelopmental and genetic disorders.
- Evaluating a targeted treatment for MCAP syndrome
- Studying whether therapy can improve adaptive behavior over time
- Advancing care for rare genetic and developmental conditions
These trials are intended to help clarify the potential of precision medicine in a rare disease setting where treatment options remain limited.
Acute Myeloid Leukemia and Hematologic Cancer Studies
Research at this hospital also includes Neoplasms involving Acute Myeloid Leukemia, with studies focused on improving remission rates and treatment effectiveness. The goal is to determine whether newer approaches can lead to deeper and more durable responses in patients with this aggressive blood cancer.
- Comparing treatment strategies for newly diagnosed AML
- Measuring whether patients achieve deep remission after induction therapy
- Exploring better outcomes in genomically defined acute leukemia
This work supports ongoing efforts to refine hematologic cancer care by identifying approaches that may improve remission quality and overall treatment benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1BeOne Medicines AG1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Of Clermont-Ferrand
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alpelisib | 1 | Unknown | 2022-11-03 | 2022-11-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.